Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J. Jackson, Mikhail Zibinsky, Delia Bradford et al.|Journal of Medicinal Chemistry|2022Cited by 12